We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,799.00
Bid: 1,805.00
Ask: 1,807.00
Change: 10.00 (0.56%)
Spread: 2.00 (0.111%)
Open: 1,786.00
High: 1,807.00
Low: 1,763.00
Prev. Close: 1,789.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

20 Jun 2016 07:00

RNS Number : 6181B
Hikma Pharmaceuticals Plc
20 June 2016
 

Annex DTR3

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

 

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

 

HIKMA PHARMACEUTICALS PLC

2.

State whether the notification relates to (i) a

transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

 

(i) & (iii)

3.

Name of person discharging managerial

responsibilities/director

 

SAID DARWAZAH

 

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

 

N/A

 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial

interest 1

 

3 ABOVE

 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

 

ORDINARY SHARES OF 10P EACH

 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

 

VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED

 

8.

State the nature of the transaction

 

PURCHASE OF 70,000 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE.

9.

Number of shares, debentures or financial

instruments relating to shares acquired

 

70,000

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

0.01%

 

11.

Number of shares, debentures or financial

instruments relating to shares disposed

 

N/A

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

N/A

 

13.

Price per share or value of transaction

 

£21.65p

14.

Date and place of transaction

 

15 - 17 JUNE 2016, LONDON

 

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

 

13,280,927 (5.55%) COMPRISING:

 

DIRECTLY, INCLUDING CONNECTED PERSONS: 745,383 (0.31%)

 

INDIRECTLY THROUGH DARHOLD LIMITED: 12,535,544 (5.24%)

16.

Date issuer informed of transaction

 

 

17 JUNE 2016

 

If a person discharging managerial responsibilities has been granted options by the issuer

complete the following boxes

 

17.

Date of grant

 

 

N/A

18.

Period during which or date on which exercisable

 

N/A

19.

Total amount paid (if any) for grant of the option

 

N/A

20.

Description of shares or debentures involved (class and number)

 

N/A

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

 

N/A

22.

Total number of shares or debentures over which options held following notification

 

 

N/A

23.

Any additional information

 

 

N/A

24.

Name of contact and telephone number for queries

 

PETER SPEIRS 0207 399 2772

 

 

 

Name of authorised official of issuer responsible for making notification

 

Peter Speirs, Company Secretary

 

Date of notification 20 June 2016

 

 

Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.

 

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

 

Annex DTR3

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

 

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

 

HIKMA PHARMACEUTICALS PLC

2.

State whether the notification relates to (i) a

transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

 

(i) & (iii)

3.

Name of person discharging managerial

responsibilities/director

 

MAZEN DARWAZAH

 

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

 

N/A

 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial

interest 1

 

3 ABOVE

 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

 

ORDINARY SHARES OF 10P EACH

 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

 

VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED

 

8.

State the nature of the transaction

 

PURCHASE OF 70,000 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE.

9.

Number of shares, debentures or financial

instruments relating to shares acquired

 

70,000

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

0.01%

 

11.

Number of shares, debentures or financial

instruments relating to shares disposed

 

N/A

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

N/A

 

13.

Price per share or value of transaction

 

£21.65p

14.

Date and place of transaction

 

15 - 17 JUNE 2016, LONDON

 

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

 

7,263,704 (3.03%) COMPRISING:

 

DIRECTLY: 952,965 (0.40%)

 

INDIRECTLY THROUGH DARHOLD LIMITED: 6,310,739 (2.63%)

16.

Date issuer informed of transaction

 

 

17 JUNE 2016

 

If a person discharging managerial responsibilities has been granted options by the issuer

complete the following boxes

 

17.

Date of grant

 

 

N/A

18.

Period during which or date on which exercisable

 

N/A

19.

Total amount paid (if any) for grant of the option

 

N/A

20.

Description of shares or debentures involved (class and number)

 

N/A

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

 

N/A

22.

Total number of shares or debentures over which options held following notification

 

 

N/A

23.

Any additional information

 

 

N/A

24.

Name of contact and telephone number for queries

 

PETER SPEIRS 0207 399 2772

 

 

 

Name of authorised official of issuer responsible for making notification

 

Peter Speirs, Company Secretary

 

Date of notification 20 June 2016

 

 

Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.

 

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

 

 

Annex DTR3

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

 

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

 

HIKMA PHARMACEUTICALS PLC

2.

State whether the notification relates to (i) a

transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

 

(i) & (iii)

3.

Name of person discharging managerial

responsibilities/director

 

MOHAMMED 'ALI' AL-HUSRY

 

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

 

N/A

 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial

interest 1

 

3 ABOVE

 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

 

ORDINARY SHARES OF 10P EACH

 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

 

VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED

 

8.

State the nature of the transaction

 

PURCHASE OF 70,000 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE.

9.

Number of shares, debentures or financial

instruments relating to shares acquired

 

70,000

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

0.01%

 

11.

Number of shares, debentures or financial

instruments relating to shares disposed

 

N/A

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

N/A

 

13.

Price per share or value of transaction

 

£21.65p

14.

Date and place of transaction

 

15 - 17 JUNE 2016, LONDON

 

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

 

5,802,236 (2.42%) UNDER DYKB LIMITED COMPRISING:

 

DIRECTLY: 1,162,811 (0.49%)

 

INDIRECTLY THROUGH DARHOLD LIMITED: 4,639,425 (1.93%)

16.

Date issuer informed of transaction

 

 

17 JUNE 2016

 

If a person discharging managerial responsibilities has been granted options by the issuer

complete the following boxes

 

17.

Date of grant

 

 

N/A

18.

Period during which or date on which exercisable

 

N/A

19.

Total amount paid (if any) for grant of the option

 

N/A

20.

Description of shares or debentures involved (class and number)

 

N/A

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

 

N/A

22.

Total number of shares or debentures over which options held following notification

 

 

N/A

23.

Any additional information

 

 

N/A

24.

Name of contact and telephone number for queries

 

PETER SPEIRS 0207 399 2772

 

 

 

Name of authorised official of issuer responsible for making notification

 

Peter Speirs, Company Secretary

 

Date of notification 20 June 2016

 

 

Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.

 

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHGCGDLLGBBGLC
Date   Source Headline
17th Apr 202410:42 amRNSDirector/PDMR Shareholding
15th Apr 20244:43 pmRNSHikma appoints new President of Generics business
11th Apr 202410:58 amRNSDirector/PDMR Shareholding
2nd Apr 20249:50 amRNSBlock listing Interim Review
22nd Mar 20249:21 amRNSAnnual Financial Report and Notice of AGM
13th Mar 20249:42 amRNSDirector/PDMR Shareholding
7th Mar 20241:52 pmRNSDirector/PDMR Shareholding
1st Mar 202410:17 amRNSTotal Voting Rights
22nd Feb 20247:00 amRNSFinal Results
5th Feb 20248:46 amRNSNotice of Results
1st Feb 20246:22 pmRNSAgreement in Principle for US Opioid Settlement
1st Feb 202412:08 pmRNSTotal Voting Rights
2nd Jan 20243:24 pmRNSTotal Voting Rights
29th Dec 20237:00 amRNSCompany Secretary Change
1st Dec 20237:00 amRNSTotal Voting Rights
2nd Nov 20237:00 amRNSTrading Statement
2nd Oct 202310:13 amRNSBlock listing Interim Review
2nd Oct 202310:04 amRNSTotal Voting Rights
1st Sep 20237:00 amRNSTotal Voting Rights
31st Aug 20234:14 pmRNSDirector/PDMR Shareholding
11th Aug 20232:00 pmRNSDirector/PDMR Shareholding
10th Aug 20234:53 pmRNSDirector/PDMR Shareholding
3rd Aug 20237:00 amRNSHalf-year Report
17th Jul 20239:11 amRNSNotice of Results
14th Jun 202310:03 amRNSHolding(s) in Company
8th Jun 202310:25 amRNSDirector/PDMR Shareholding
31st May 20233:20 pmRNSDirector/PDMR Shareholding
23rd May 20234:14 pmRNSHolding(s) in Company
17th May 20239:56 amRNSDirector/PDMR Shareholding
2nd May 202310:53 amRNSTotal Voting Rights
28th Apr 20233:25 pmRNSResult of AGM
28th Apr 20237:00 amRNSTrading Statement
24th Apr 20234:15 pmRNSDirector/PDMR Shareholding
12th Apr 20237:00 amRNSDirectorate Change
3rd Apr 20239:27 amRNSBlock listing Interim Review
3rd Apr 20239:19 amRNSTotal Voting Rights
16th Mar 202310:17 amRNSAnnual Financial Report and Notice of AGM
2nd Mar 20239:30 amRNSTotal Voting Rights
23rd Feb 20237:00 amRNSFinal Results
17th Feb 202310:20 amRNSHolding(s) in Company
7th Feb 20239:36 amRNSNotice of Results
1st Feb 202310:18 amRNSTotal Voting Rights
18th Jan 202310:16 amRNSDirector/PDMR Shareholding
18th Jan 20239:39 amRNSHolding(s) in Company
17th Jan 202311:58 amRNSHolding(s) in Company
10th Jan 20233:42 pmRNSAdditional Listing
10th Jan 20239:20 amRNSDirector/PDMR Shareholding
3rd Jan 20239:23 amRNSTotal Voting Rights
3rd Jan 20237:00 amRNSHikma launches sodium oxybate in the US
1st Dec 20229:24 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.